CCL2 and central nervous system cancer: These results were corroborated by Zhu et al. who directly blocked CCL2 with a monoclonal antibody in C57BL/6 mice bearing intracranial either GL261 or U87 glioma cancer cells and found that blockade of CCL2 led to an increase in median survival in both mouse models (30).